Bioadaptives (BDPT) Equity Average (2019 - 2025)
Historic Equity Average for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$1.3 million.
- Bioadaptives' Equity Average rose 3022.65% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year increase of 3022.65%. This contributed to the annual value of -$1.6 million for FY2024, which is 40.08% down from last year.
- Per Bioadaptives' latest filing, its Equity Average stood at -$1.3 million for Q3 2025, which was up 3022.65% from -$1.4 million recorded in Q2 2025.
- In the past 5 years, Bioadaptives' Equity Average registered a high of -$1.2 million during Q4 2021, and its lowest value of -$1.9 million during Q3 2024.
- Moreover, its 5-year median value for Equity Average was -$1.4 million (2022), whereas its average is -$1.5 million.
- As far as peak fluctuations go, Bioadaptives' Equity Average plummeted by 3273.41% in 2021, and later surged by 3022.65% in 2025.
- Over the past 5 years, Bioadaptives' Equity Average (Quarter) stood at -$1.2 million in 2021, then crashed by 32.19% to -$1.5 million in 2022, then grew by 8.36% to -$1.4 million in 2023, then dropped by 17.07% to -$1.6 million in 2024, then increased by 20.46% to -$1.3 million in 2025.
- Its last three reported values are -$1.3 million in Q3 2025, -$1.4 million for Q2 2025, and -$1.5 million during Q1 2025.